Congrats to our SOSV portfolio company VALANX Biotech on its €3 million in new funding to advance its lead antibody-drug conjugate (ADC) program. The financing was led by Fournier-Majoie Foundation and FUJIFILM Corporation with participation from SOSV, XISTA Science Ventures, tecnet equity, Urs Spitz, and Skygene.

The financing will enable pre-clinical development of VLX-ADC-001, a LIV-1-targeting ADC for metastatic triple-negative breast cancer (mTNBC), with candidate selection planned for June 2026, while also supporting GMP readiness and partnering activities for the company’s GoldenSite conjugation platform.